ArticleOphthalmology science2026
Effect of Low-Concentration Atropine Eye Drops on Parapapillary Gamma Zone Development and Enlargement over 3 Years: The LAMP Study.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Low-Concentration Atropine for Myopia Management: Recent Evidence and Clinical Implications.Ophthalmology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the longitudinal changes in the parapapillary gamma zone in children receiving 0.05%, 0.025%, or 0.01% atropine eye drops and placebo/switchover over 3 years based on the Low-Concentration Atropine for Myopia Progression (LAMP) study. Design: A secondary analysis from a randomized controlled trial. Participants: Two hundred eighty children underwent spectral-domain OCT at baseline, which involved 24 equally spaced radial OCT B-scans of the optic nerve head, taken at 1-year intervals. Methods: Children in the LAMP study were randomized to receive 0.05%, 0.025%, 0.01% atropine, or placebo eye drops. In the second year, placebo participants switched to 0.05% atropine. At the beginning of the third year, each group was rerandomized to continued treatment or cessation (washout). The Bruch membrane opening was identified in 48 meridians in each eye. Gamma zone was defined as the parapapillary region without Bruch membrane. Main Outcome Measures: Differences between treatment groups in gamma zone area changes from baseline to the 3-year follow-up visits. Results: Of 238 children included at baseline, the study included 192 (80.7%) children completing the follow-up of 3 years. The cumulative mean gamma zone area changes differed significantly between the initial 0.05%, 0.025%, and 0.01% atropine subgroups (0.09 ± 0.09 mm Conclusions: Low-concentration atropine reduced parapapillary gamma zone enlargement in a concentration-dependent manner over a 3-year treatment period. Continued 0.05% atropine treatment showed efficacy in controlling gamma zone development. Financial Disclosures: The author has no/the authors have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.